Analgesia News and Research

RSS

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

Covidien, a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) recently granted approval to the company's Mallinckrodt business for morphine sulfate oral solution, used to relieve moderate to severe acute and chronic pain in opioid-tolerant patients. The solution will be available as a generic in 100 milligrams per 5 mL (20 milligrams per 1 mL).

1 Aug 2011

Anesthetic agent isoflurane may treat intracerebral hemorrhage

The anesthetic agent isoflurane may be a useful treatment for intracerebral hemorrhage (ICH)—a type of stroke caused by bleeding inside the brain, reports a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

26 Jul 2011

Diabetes drug rosiglitazone can reduce development of neuropathic pain

The diabetes drug rosiglitazone (Avandia) can control inflammation leading to nerve damage and abnormal pain responses, suggests a paper in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

26 Jul 2011

Patients with pulmonary hypertension more likely to have complications after bilateral TKA

A new study by researchers at Hospital for Special Surgery has identified patients who are at a higher risk of morbidity and mortality when undergoing knee replacement surgery in both legs at the same time.

15 Jul 2011

Anesthesia & Analgesia achieves significant increase in Impact Factor

Anesthesia & Analgesia, the official journal of the International Anesthesia Research Society (IARS), reports continued increase in its Impact Factor, the rating of academic and scientific journals tracked and published annually by Thomson Reuters.

14 Jul 2011

Poisonous shrub extract may act as natural painkiller

An extract of the poisonous shrub Jatropha curcas acts as a strong painkiller and may have a mode of action different from conventional analgesics, such as morphine and other pharmaceuticals.

12 Jul 2011

APP receives FDA approval to market Clonidine Hydrochloride Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Clonidine Hydrochloride Injection in two dosage strengths.

11 Jul 2011

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced receipt from Mallinckrodt Inc., a Covidien company (Covidien), of top-line results from a Phase 2 study conducted by Covidien, of twice-daily administration of PENNSAID Viscous Solution (topical diclofenac sodium viscous solution) 2% w/w, previously referred to as PENNSAID Gel.

30 Jun 2011

FDA clears Nuvo's IND for Lidocaine Spray formulation

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application filed May 27, 2011 for a novel topical Lidocaine Spray formulation (NRI-ANA), allowing for initiation of Phase 1 studies.

29 Jun 2011

Intravenous diclofenac holds promise against severe pain following oral surgery

An essential aspect of oral surgery is controlling the patient's pain following a procedure. The goal is to relieve pain and promote a rapid recovery, without opioid side effects. An initial study shows that Dyloject, a new intravenous form of the drug diclofenac, has promise for achieving these goals.

27 Jun 2011

Automated screening system helps identify cases of unexpected drug diversions

Electronic data from automated drug dispensing carts can help to identify drug diversion by anesthesia care providers, according to a report in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Jun 2011

PCIB reports main results of Amphinex Phase I/II study against multiple cancers

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.

24 Jun 2011

Hypertension variability during cardiac surgery may increase risk of death

For patients with hypertension undergoing heart surgery, large variations in blood pressure before, during, and after the operation are associated with an increased risk of death, reports the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Jun 2011

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Endo Pharmaceuticals announced today that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan. 7, 2011 Action Letter relating to Endo's new drug application (NDA) for a new formulation of OPANA ER has been accepted.

24 Jun 2011

Inducing labor does not increase risk of emergency cesarean section

A new study published in the international Nordic journal Acta Obstetricia et Gynecologica Scandinavica (AOGS) reveals that inducing labor in the weeks around term, or from week 39 to week 41, is not connected with higher rates of cesarean section compared with waiting for a later spontaneous or induced labor.

21 Jun 2011

APP announces $38 million expansion of New York manufacturing facility

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today a $38 million expansion of its Grand Island, New York manufacturing facility.

15 Jun 2011

FDA extends Pacira's EXPAREL PDUFA goal date by three months

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for EXPAREL by three months.

14 Jun 2011

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Adolor Corporation today announced that it has completed enrollment in its Phase 2 clinical evaluation of ADL5945 in chronic, non-cancer pain patients with opioid-induced constipation (OIC).

6 Jun 2011

Nano-formulated indomethacin at lower dose effective in treating pain

A novel, lower-dose formulation of indomethacin, a widely used pain reliever, is absorbed faster by the body than a standard formulation and maintains comparable maximum concentrations in the blood despite being administered at a lower dose, according to a study to be reported here tomorrow at the annual meeting of the American Headache Society.

4 Jun 2011

Plasma resuscitation restores damage to endothelial glycocalyx after hemorrhagic shock

Using plasma rather than standard resuscitation fluids seems to improve survival in trauma patients with massive blood loss. Now a new study in animals suggests that this benefit may result from plasma's ability to restore the "endothelial glycocalyx," a special layer lining the blood vessels, reports the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

1 Jun 2011